

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

MESSADEK, Jallal

Serial No. :

Filed:

GLYCINE BETAINE AND ITS USE

Docket No. 31927-CIP2

Group Art Unit No.

Examiner:

---

Commissioner of Patents  
Alexandra, VA 22313-1450

Sir:


INFORMATION DISCLOSURE STATEMENT

The attached references are being filed to fulfill the duty of candor and good faith toward the Patent and Trademark Office, as required by 37 C.F.R. §1.56.

Respectfully submitted,

HOVEY WILLIAMS LLP

By

  
Thomas H. Van Hoozer, Reg. No. 32,761  
2405 Grand Boulevard, Suite 400  
Kansas City, Missouri 64108  
(816) 474-9050

FORM PTO-1449 (Rev. 2-32)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	ATTY. DOCKET NO. 31927-CIP2	SERIAL NO.
	APPLICANT: MESSADEK, Jallal	
	FILING DATE:	GROUP:

### U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 8 8 0 0 9 8	09.03.99	Häussinger			

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	9 7 0 6 7 9 5	27.02.97	WO				
	0 7 8 1 5 5 4	23.07.96	EPO				
	9 8 1 9 6 9 0	06.11.96	WO				
	9 5 1 5 7 5 0	10.12.93	WO				
	9 7 3 8 6 8 5	12.04.96	WO				
	0 3 4 7 8 6 4	20.06.89	EPO				
	0 0 2 5 7 6 4	30.10.98	WO				
	2 1 0 1 2 2 B	28.09.92	HU				
1	0 3 2 1 9 8 4	11.12.98	JP				
0	9 9 0 0 1 6 4	05.12.00	BE				
	0 0 5 1 5 9 6	08.09.00	WO				
	0 3 4 9 9 0 2	29.06.89	EPO				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Savi et al.; Article from Entrez-PubMed web page entitled: SR 121787, a new orally active fibrinogen receptor antagonist; Sep, 80(3):469-76.
	Banno et al.; Article from Entrez-PubMed web page entitled: Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist; Eur J Pharmacol 1999 Feb 19; 367 (2-3): 275-82.
	Ramjit et al.; Article from Entrez-PubMed web page entitled: Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis; J Pharmacol Exp Ther 1993, Sep; 266(3): 1501-11.
	Savi et al.; Article from Entrez-PubMed7.htm web page entitled: SR121787, a new orally active fibrinogen receptor antagonist; Thromb Haemost 1998 Sep; 80(3): 469-76.
	Hoffmann et al.; Article from Entrez-PubMed web page entitled: SR 121787, Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagoist; J Pharmacol Exp Ther 1998 Aug; 286(2): 670-5.
	Packham; Article from Entrez-PubMed web page entitled: Role of platelets in thrombosis and hemostasis; Can J Physiol Pharmacol 1994; Mar; 72(3): 278-84.
	Lynch et al.; Article from Entrez-PubMed web page entitled: Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383; J Pharmacol Exp Ther 1995 Jan; 272(1): 20-32.
	Takada et al.; Article from Entrez-PubMed web page entitled: The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.

		Article from Entrez-PubMed web page entitled: antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
		XP-002123170; Database Chemabs 'Online!'; Chemical Abstracts Service, Columbus, OH; ZAPADNYUK, B.I. et al.: "Bile-secretory effect of trimethylglycine in normal and atherosclerotic animals of different ages" retrieved from STN Databas accession no. 107:190742 HCA; abstract & BYULL. EKSP. BIOL. MED. (1987), 104(7), 30-2
		XP002123171; Database Chemabs 'Online!'; Chemical Abstracts Service, Columbus, OH; PANTELEIMONOVA, T.N. et al.: "Effect of trimethylglycine on lipid metabolism in rabbits with experimental atherosclerosis" retrieved from STN; Database accession no. 99:99080 HCA; abstract & FARMAKOL. TOKSIKOL. (MOSCOW) (1983), 46(4), 83-5
		XP-000853747; Fazio B Et al: "Treatment of human atherosclerosis with betaine." MINERVA MED, (1961 APR 25) 52 1511-6., the whole document
		XP-002123167; P.H. List et al.: "HAGERS HANDBUCH DER PHARMAZEUTISCHEN PRAXIS" 1972, SPRINGER-VERLAG, BERLIN HEIDELBERG, NEW YORK, page 431
		XP000853853; "Betaine for homocystinuria." MEDICAL LETTER ON DRUGS AND THERAPEUTICS, (1997); 39/993 (12)., the whole document
		XP000853897; WILCKEN D E ET AL: "The natural history of vascular disease in homocystinuria and the effects of treatment." JOURNAL OF INHERITED METABOLIC DISEASE, (1997 JUN) 20 (2) 295-300., the whole document
		XP-002123168; J.E.F. REYNOLDS: "MARTINDALE, The Extra Pharmacopoeia";1996, ROYAL PHARMACEUTICAL SOCIETY, LONDON;"Betaine hydrochloride"; page 1679
		XP002123169; "the merck index"; 1996, MERCK & CO, WHITHOUSE STATIONS, NJ; "Betaine"; page 198
		Mar et al.; Betaine in wine: answer to the French paradox?; Med Hypothese 1999 Nov; 53(5):383-5
		Salamone et al.; Changes in blood coagulation in experimental subacute poisoning with p-dichlorobenzene. The influence of some lipotropic factors; Journal; Answer 13 of 13; Copyright 2003
		XP001080754; Vinson et al.; New Drug Approvals of 1996 - Part 3; University of Mississippi School of Pharmacy; Drug Topics; March 17, 1997; pages 72-81.
		XP-002202249; Napreben; Pharmaprojects; Applied Pharma Research; Company communication, APR, Sep 1995; whole document.
		Matthews et al.; An indirect response model for homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria; copyright 2002 Blackwell Science Ltd. Br J Clin Pharmacol, 54, 140-146.
		Schwahn et al.; Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria; copyright 2003 Blackwell Science Ltd. Br J Clin Pharmacol, 55, 6-13.
		Naproxen monography from <a href="http://rxlist.com/">http://rxlist.com/</a> ; Clinical Pharmacology; 2 pages
		Bandfield et al.; Naproxen, Naproxen Sodium, and Naproxen Betainate Sodium Monohydrate Salts; Pharmaceutics I; April 14, 2001; 5 pages
		van Hecken et al.; Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers; Drug Metabol Drug Interact 1998; 14 (3): 193-205.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.